- WKN: A2GS40
- ISIN: DE000A2GS401
- Land: Germany
Nachricht vom 12.04.2016 | 22:24
Software AG: Preliminary Financial Results for Q1 2016
Software AG / Key word(s): Quarter Results/Preliminary Results 12.04.2016 22:24 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.
AD-HOC-RELEASE ACCORDING TO § 15 WPHG Software AG: Preliminary Financial Results for Q1 2016 Darmstadt, Germany, April 12, 2016 - Software AG (Frankfurt TecDAX: SOW) pre-announces its preliminary financial figures (IFRS, preliminary) for the first quarter 2016: - The Company's profit before interest and taxes EBIT improved by 55 percent to EUR 45.3 (Q1 2015: EUR 29.3) million. - The Group's operating earnings (EBITA, non-IFRS) increased by 23 percent to EUR 59.1 (Q1 2015: EUR 48.1) million; accordingly the operating earnings margin (EBITA, non-IFRS) reached 29 (Q1 2015: 25) percent. - Software AG's total revenue improved by 9 percent at constant currency to EUR 206.2 million. - The Company's license sales increased by 31 percent at constant currency to EUR 59.1 million. - The Group's product revenue (license & maintenance) increased by 11 percent at constant currency to EUR158.0 million. - The revenue in the database business line Adabas & Natural (A&N) improved by +20 percent at constant currency to EUR 63.6 million. - Total sales of the Digital Business Platform (DBP) improved by +6 percent at constant currency to EUR 94.6 million. - Additionally, the order entry in the cloud business increased by more than 150 percent. Including this development, the digital new business (DBP licenses + Cloud order entry) recorded double-digit growth. - The revenue in the Consulting business line increased by 2 percent at constant currency to EUR 48.0 million - Based on the positive business development in the first quarter, the executive management board of Software AG confirmed the outlook for the full year 2016.in EUR millions Q1/2016 Q1/2015 ∆ in % ∆ in % as stated net of currency Total revenue 206.2 194.1 +6 +9 Product revenue 158.0 146.2 +8 +11 Maintenance revenue 98.9 99.7 -1 +2 License revenue 59.1 46.5 +27 +31 Digital Business Platform 94.6 91.0 +4 +6 as % of total revenue 46% 47% DBP maintenance 61.9 59.9 +3 +5 DBP licenses 32.7 31.1 +5 +7 Adabas & Natural 63.6 55.4 +15 +20 as % of total revenue 31% 29% A&N maintenance 37.0 39.8 -7 -4 A&N licenses 26.4 15.5 +70 +79 Consulting 48.0 47.7 +1 +2 as % of total revenue 23% 25% EBIT* 45.3 29.3 +55 as % of total revenue 22% 15% Operating Earnings (EBITA, 59.1 48.1 +23 non-IFRS) ** as % of total revenue 29% 25%* = consolidated net income + income tax + other tax + financial result ** = EBITA adjusted for reduction of acquisition-related product revenue by purchase price allocation, other acquisition effects, share-based payment, restructuring/severance payments and operating income of divested units Please note: On April 13th, 2016 at 09:00 am CET, Software AG will hold a conference call for investors, analysts and journalists. Dial-in details can be found on the Corporate Website in the Investor Relations section. 12.04.2016 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de
Language: English Company: Software AG Uhlandstraße 12 64297 Darmstadt Germany Phone: +49 (0)6151 92-1900 Fax: +49 (0)6151 92-34 1899 E-mail: Investor.Relations@softwareag.com Internet: www.softwareag.com ISIN: DE0003304002 WKN: 330400 Indices: TecDAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart; Terminbörse EUREX End of Announcement DGAP News-Service
GBC im Fokus
IGEA Pharma N.V. Realignment to CBD extraction
The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.
Der AKTIONÄR News
03. Dezember 18:19 Musterdepot-Titel BHP: Es geht voran
03. Dezember 19:02 Dow Jones: Es hört nicht auf...
03. Dezember 19:50 Commerzbank und Deutsche Bank: "Bitte keine großzügige ...
03. Dezember 20:20 Apple unter Druck – aber die Lage hellt sich langsam auf
03. Dezember 21:33 Schlussglocke: Dow Jones schließt schwache Woche mit weiterem Minus ab
News im Fokus
Allianz SE: Allianz kündigt Abschluss eines Rückversicherungsvertrages in den USA an
03. Dezember 2021, 07:03
FY 2020/2021 Financial Results
16. Dezember 2021
Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen
02. Dezember 2021